SI-BONE, Inc.
NGM: SIBNLive Quote
📈 ZcoreAI Score
Our AI model analyzes SI-BONE, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SIBN Z-Score →About SI-BONE, Inc.
Healthcare
Medical Devices
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
📊 Fundamental Analysis
SI-BONE, Inc. demonstrates a profit margin of -9.4%, which is below the sector average, suggesting competitive pressure.
The company recently reported 15.0% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is -11.0%, which indicates that capital utilization is currently under pressure.
At a current price of $12.84, SIBN currently trades near the bottom of its 52-week range (7%), indicating potential value or weakness (Range: $12.15 - $21.89).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$567.08M
Trailing P/E
--
Forward P/E
-33.66
Beta (5Y)
0.77
52W High
$21.89
52W Low
$12.15
Avg Volume
597K
Day High
Day Low